Table 1.
Neutralizing antibody response (plaque-reduction neutralization test (PRNT50) and ELISA) in patients with coronavirus disease 2019 (COVID-19) according to time from diagnosis
| 140 d |
187 d |
271 da |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Male (n = 43) | Female (n = 68) | Total (n = 111) | Male (n = 39) | Female (n = 63) | Total (n = 102) | Male (n = 43) | Female (n = 66) | Total (n = 109) | |
| PRNT titre | |||||||||
| 40 | 4 (9.3%) | 16 (23.5%) | 20 (18.0%) | 12 (30.8%) | 16 (25.4%) | 28 (27.5%) | 9 (20.9%) | 13 (19.7%) | 22 (20.2%) |
| 80 | 13 (30.2%) | 9 (13.2%) | 22 (19.8%) | 8 (20.5%) | 7 (11.1%) | 15 (14.7%) | 11 (25.6%) | 11 (16.7%) | 22 (20.2%) |
| 160 | 8 (18.6%) | 4 (5.9%) | 12 (10.8%) | 6 (15.4%) | 9 (14.3%) | 15 (14.7%) | 4 (9.3%) | 9 (13.6%) | 13 (11.9%) |
| 320 | 5 (11.6%) | 11 (16.2%) | 16 (14.4%) | 4 (10.2%) | 6 (9.5%) | 10 (9.8%) | 3 (7.0%) | 7 (10.6%) | 10 (9.2%) |
| 640 | 3 (7.0%) | 7 (10.3%) | 10 (9.0%) | 2 (5.1%) | 7 (11.1%) | 9 (8.8%) | 1 (2.3%) | 3 (4.5%) | 4 (3.7%) |
| 1280 | 1 (2.3%) | 4 (5.9%) | 5 (4.5%) | 0 (0.0%) | 1 (1.6%) | 1 (0.9%) | 0 (0.0%) | 1 (1.5%) | 1 (0.9%) |
| Negative (<20) Positive |
9 (20.9%) 34 (79.1%) |
17 (25.0%) 51 (75.0%) |
26 (23.4%) 85 (76.6%) |
7 (17.9%) 32 (82.1%) |
17 (27.0%) 46 (73.0%) |
24 (23.5%) 78 (76.5%) |
15 (34.9%) 28 (65.1%) |
22 (33.3%) 44 (66.7%) |
37 (33.9%) 72 (66.1%) |
|
140 d |
187 da |
271 da |
|||||||
| nAb on ELISA | |||||||||
| Negative | 10 (23.3%) | 19 (27.9%) | 29 (26.1%) | 16 (41.0%) | 20 (31.7%) | 36 (35.3%) | 17 (39.5%) | 22 (33.3%) | 39 (35.8%) |
| Positive | 33 (76.7%) | 49 (72.1%) | 82 (73.9%) | 23 (59.0%) | 43 (68.3%) | 66 (64.7%) | 26 (60.5%) | 44 (66.7%) | 70 (64.2%) |
ELISA, enzyme-linked immunosorbent assay; nAb, neutralizing antibody.
a
p < 0.05 compared to mean of 140 d.